Lv1
36 积分 2024-10-29 加入
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
17小时前
待确认
The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders
6天前
已完结
A Brief Overview of Global Trends in MSC-Based Cell Therapy
3个月前
已完结
Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019
4个月前
已完结
Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019
4个月前
已完结
Model-Informed Dosing Regimen of Sugemalimab for European Patients With Non-Small Cell Lung Cancer: Bridging From Asian Clinical Data
4个月前
已完结
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
5个月前
已完结
Envafolimab: First Approval
6个月前
已完结
PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions
9个月前
已完结
Evaluation of Hemoglobin Response to Treatment With Enarodustat Using Pharmacometric Approach in Japanese Anemic Patients With Chronic Kidney Disease
1年前
已完结
皖公网安备34019202002308
